BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 38250045)

  • 1. [
    Gallegos CA; Lu Y; Clements JC; Song PN; Lynch SE; Mascioni A; Jia F; Hartman YE; Massicano AVF; Houson HA; Lapi SE; Warram JM; Markert JM; Sorace AG
    Theranostics; 2024; 14(3):911-923. PubMed ID: 38250045
    [No Abstract]   [Full Text] [Related]  

  • 2. Positron emission tomography imaging with
    Kasten BB; Houson HA; Coleman JM; Leavenworth JW; Markert JM; Wu AM; Salazar F; Tavaré R; Massicano AVF; Gillespie GY; Lapi SE; Warram JM; Sorace AG
    Sci Rep; 2021 Jul; 11(1):15384. PubMed ID: 34321569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4
    Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
    Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immuno-PET Monitoring of CD8
    Alsaid H; Cheng SH; Bi M; Xie F; Rambo M; Skedzielewski T; Hoang B; Mohanan S; Comroe D; Gehman A; Hsu CY; Farhangi K; Tran H; Sherina V; Doan M; Groseclose MR; Hopson CB; Brett S; Wilson IA; Nicholls A; Ballas M; Waight JD; Jucker BM
    Mol Imaging Biol; 2023 Jun; 25(3):528-540. PubMed ID: 36266600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical ImmunoPET Imaging of Glioblastoma-Infiltrating Myeloid Cells Using Zirconium-89 Labeled Anti-CD11b Antibody.
    Nigam S; McCarl L; Kumar R; Edinger RS; Kurland BF; Anderson CJ; Panigrahy A; Kohanbash G; Edwards WB
    Mol Imaging Biol; 2020 Jun; 22(3):685-694. PubMed ID: 31529407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.
    Bommareddy PK; Wakimoto H; Martuza RL; Kaufman HL; Rabkin SD; Saha D
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38599661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.
    Saha D; Martuza RL; Rabkin SD
    Immunotherapy; 2018 Jul; 10(9):779-786. PubMed ID: 30008259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
    Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
    J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses.
    Alayo QA; Ito H; Passaro C; Zdioruk M; Mahmoud AB; Grauwet K; Zhang X; Lawler SE; Reardon DA; Goins WF; Fernandez S; Chiocca EA; Nakashima H
    Sci Rep; 2020 Mar; 10(1):5095. PubMed ID: 32198420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma.
    Nisnboym M; Vincze SR; Xiong Z; Sneiderman CT; Raphael RA; Li B; Jaswal AP; Sever RE; Day KE; LaToche JD; Foley LM; Karimi H; Hitchens TK; Agnihotri S; Hu B; Rajasundaram D; Anderson CJ; Blumenthal DT; Pearce TM; Uttam S; Nedrow JR; Panigrahy A; Pollack IF; Lieberman FS; Drappatz J; Raphael I; Edwards WB; Kohanbash G
    Cancer Res Commun; 2023 Jul; 3(7):1173-1188. PubMed ID: 37426447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PET-Tracer
    Griessinger CM; Olafsen T; Mascioni A; Jiang ZK; Zamilpa C; Jia F; Torgov M; Romero JM; Marchioni F; Satpayev D; Lee C; Zhang G; Nayak TK; Pincha M; Amann M; Mohan PLB; Richard M; Nicolini VG; Sam J; Claus C; Ferrara C; Brünker P; Bacac M; Umana P; Rüttinger D; Wilson IA; Gudas J; Klein C; Tessier JJL
    Cancer Res; 2020 Jul; 80(13):2903-2913. PubMed ID: 32409308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ImmunoPET imaging of TIGIT in the glioma microenvironment.
    Vincze SR; Jaswal AP; Frederico SC; Nisnboym M; Li B; Xiong Z; Sever RE; Sneiderman CT; Rodgers M; Day KE; Latoche JD; Foley LM; Hitchens TK; Frederick R; Patel RB; Hadjipanayis CG; Raphael I; Nedrow JR; Edwards WB; Kohanbash G
    Sci Rep; 2024 Mar; 14(1):5305. PubMed ID: 38438420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of
    Farwell MD; Gamache RF; Babazada H; Hellmann MD; Harding JJ; Korn R; Mascioni A; Le W; Wilson I; Gordon MS; Wu AM; Ulaner GA; Wolchok JD; Postow MA; Pandit-Taskar N
    J Nucl Med; 2022 May; 63(5):720-726. PubMed ID: 34413145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.
    Saha D; Wakimoto H; Peters CW; Antoszczyk SJ; Rabkin SD; Martuza RL
    Clin Cancer Res; 2018 Jul; 24(14):3409-3422. PubMed ID: 29599413
    [No Abstract]   [Full Text] [Related]  

  • 15. Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade.
    Nair S; Mazzoccoli L; Jash A; Govero J; Bais SS; Hu T; Fontes-Garfias CR; Shan C; Okada H; Shresta S; Rich JN; Shi PY; Diamond MS; Chheda MG
    JCI Insight; 2021 Jan; 6(1):. PubMed ID: 33232299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Evaluation of
    Maresca KP; Chen J; Mathur D; Giddabasappa A; Root A; Narula J; King L; Schaer D; Golas J; Kobylarz K; Rosfjord E; Keliher E; Chen L; Ram S; Pickering EH; Hardwick JS; Rejto PA; Hussein A; Ilovich O; Staton K; Wilson I; McCarthy TJ
    Mol Imaging Biol; 2021 Dec; 23(6):941-951. PubMed ID: 34143379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [
    Nagle VL; Henry KE; Hertz CAJ; Graham MS; Campos C; Parada LF; Pandit-Taskar N; Schietinger A; Mellinghoff IK; Lewis JS
    Clin Cancer Res; 2021 Apr; 27(7):1958-1966. PubMed ID: 33495310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
    Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
    Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of immune responses after immunotherapy in glioblastoma using PET and MRI.
    Antonios JP; Soto H; Everson RG; Moughon DL; Wang AC; Orpilla J; Radu C; Ellingson BM; Lee JT; Cloughesy T; Phelps ME; Czernin J; Liau LM; Prins RM
    Proc Natl Acad Sci U S A; 2017 Sep; 114(38):10220-10225. PubMed ID: 28874539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models.
    Koch MS; Zdioruk M; Nowicki MO; Griffith AM; Aguilar E; Aguilar LK; Guzik BW; Barone F; Tak PP; Tabatabai G; Lederer JA; Chiocca EA; Lawler S
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.